|Day Low/High||174.02 / 176.98|
|52 Wk Low/High||151.80 / 195.81|
A group of outside experts convened by the U.S. Food and Drug Administration is meeting Tuesday to review a new combination therapy for cystic fibrosis developed by Vertex Pharmaceuticals.
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a pre-market laggard candidate
TheStreet highlights 3 stocks pushing the drugs industry higher today.
The most recent short interest data has been released by the NASDAQ for the 04/15/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2015.
Stocks are mixed on Tuesday as disappointing earnings drag on overall markets.
Mylan will generate a higher stock price for its shareholders in the coming months, deal or no deal.
Stocks are mixed on Tuesday as disappointing earnings from several large-caps overshadow a global rally.
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a strong on high relative volume candidate
Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2015 financial results on Wednesday, April 29, 2015 after the financial markets close.
Shares of PTC Therapeutics are rising this morning after Deutsche Bank compared the company's earnings power potential to another drugmaker, Vertex, and raised its price target on PTC shares.
Some of the biggest pharmaceuticals companies were some of the health care sector's worst performers in the first quarter.
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
Stocks inch higher on Friday afternoon, recovering from an earlier drop.
Markets tried for gains on Monday, but struggled for much of the day even as the dollar's decline gave extra impetus to a rally.
Stocks are modestly higher by late morning Monday as the continued decline in the U.S. dollar boosts crude prices.
Big pharmaceuticals companies are expected to unveil lots of promising drug therapies in 2015 - specifically drugs that could make billions in sales within five years.
Shares of Vertex Pharmaceuticals (VRTX) were down in morning trading Monday after the company announced its cystic fibrosis drug Kalydeco came up short of analysts' expectations in a mid-stage trial.
Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the...
Here are healthcare stocks of all shares and sizes with strong charts.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.